Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

J Nemunaitis,N Senzer,J Olivares,P Kumar,M Barve,J Kuhn,T Nemunaitis,M Magee,Y Yu,G Wallraven,B O Pappen,P B Maples

DOI: https://doi.org/10.1038/gt.2013.9

2013-01-01

Gene Therapy

Abstract:TAG vaccine is a novel ‘triad vaccine’ that involves transfection of autologous tumor with a dual plasmid, TGFβ2 antisense gene and GM-CSF gene. Patients with advanced cancer who failed standard therapy were treated. IFN-γ ELISPOT analysis (Enzyme-Linked Immunospot Assay for Interferon Gamma) using TAG autologous vaccine target cells was performed prior to vaccination and at week 12 after the third vaccination. The purpose of this assessment was to correlate the IFN-γ ELISPOT immune response with long-term survival of advanced cancer patients who received TAG vaccination. Twenty-three of 28 patients received ⩾3 TAG vaccinations (two patients withdrew consent and three had disease progression prior to the third vaccination). Eleven patients demonstrated a positive ELISPOT response (>10 spots and ⩾2 × baseline) at week 12 and 12 patients did not ( P =0.002). Median survival from time of treatment between ELISPOT-positive and -negative groups was significantly different (550 vs 159 days, P =0.036), as was median survival from the time of procurement (627 vs 257 days, respectively, P =0.043). In conclusion, the IFN-γ ELISPOT assay may provide an effective measure of immune response following treatment with ‘triad vaccines’, but additional patient numbers and/or other immune modulatory parameters are necessary for future testing.